AI-Based Pharma Co. Faces Investor Suit Over Study Woes
Artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. has been hit with a proposed shareholder class action accusing the company of failing to disclose stumbles that allegedly affected the integrity of a...To view the full article, register now.
Already a subscriber? Click here to view full article